



**A brief elaboration on
various aspects of this**



**immunology based gender
skewing of
livestock reproduction project
by **BIASSEX™ P/L****

1. State of the art of “semen sexing”

Its latest instrument:
SexedULTRA-4M™



The only competition is the laser based flow-cytometry, it separates X vs. Y sperm;

Not available for, nor applicable to pigs;

Slow, (more speed = less accuracy);


Damaged & aged sperm = low fertility;

Wasteful and really expensive.


With our **S-B DEVICES** we propose an entirely better way!

2. a) Why immunological sex biasing has not worked so far


- Inadequately capacitated sperm cannot interact with antibodies;
- Auto-capacitated sperm agglutinate in the uterus body, blocking the utero-tubal junction for other sperm;
- Un-conjugated antibodies are far too small to be subject to the peristaltic transport during the animal's oestrus (1,000:1; micro vs. nano);
- There never were any introduced sex specific antibodies in the oviduct, where they are needed to be useful.




d) How we make it work




Oviductal enzymes acting on sperm and antibody conjugates, stripping off the coats



Sperm-Oviduct interaction



Sperm capacitation and release



Acrosome reaction and fertilization

3. PTC/AU2010324528

The essences of our two main IP claims are:

Summary of the Invention

[0017] In accordance with the present invention there is provided a method for biasing sex selection, the method comprising the introduction into a uterus of a subject a volume of micro-particle conjugates, the micro-particle conjugates being proportioned so as to approximate the size and shape of spermatozoa and thereby be carried by peristaltic waves through the uterus and fallopian tubes to the infundibulum, at which point any spermatozoa present or arriving thereafter undergo capacitation and expose antigens that may be bound by anti-male antibodies provided in the micro-particle conjugates, the binding of the exposed antigens on the spermatozoa by the anti-male antibodies resulting in their inability to penetrate the *Zona Pellucida* of an egg and effect fertilisation, the micro-particle conjugates comprising a micro-particle of a biodegradable substance, to which are bound anti-male sperm antibodies, and a sacrificial coating surrounding the micro-particle and bound anti-male sperm antibodies, wherein the sacrificial coating is removed by the same enzymes in the infundibulum that cause the capacitation of the spermatozoa therein.

FACILITATING ANTIBODY TRANSPORT

DELAYING AGGLUTINATION


Internationally granted patents will give us a distinct marketing edge, since no one can imitate our sex biasing successes without infringing our IP.

4. a) S-B DEVICES


For DIY AI savvy dairy and pig breeders
& semen processing AI Centres

consisting of:

pre-mating bovine **S-B STRAWS** & porcine **S-B BOTTLES**




and two **S-B EXTENDER** flasks for obligatorily **"S-B"**
marked **STRAWS** and **TUBES**



5. a) Potential **S-B DEVICES** market

LIVESTOCK NUMBERS IN '000 IN SELECTED OECD COUNTRIES- 2017 (FAO)					
	Cattle	Sheep	Goats	Pigs	Total
•USA	99,501	7,616	1,400	60,915	169,432
•Europe (EU)	83,664	113,852	11,512	118,695	327,723
•Argentina	50,277	16,432	3,428	3,200	73,337
•Australia	26,330	124,000	200	2,490	153,020
•Canada	13,157	634	28,400	11,843	54,034
•South Africa	14,273	29,980	7,000	1,630	52,883
•New Zealand	8,772	47,595	227	340	56,934
•Japan	4,700	16	29	9,800	14,545
Subtotal	295,974	340,109	52,167	199,113	887,363
Others	1,013,883	721,484	801,065	548,556	3,294,988
World	1,309,857	1,061,593	853,232	757,669	4,182,351



- **The world's dairy cattle number over 270 Million:**
use of AI in most modern dairies (95%) at over 1.5 doses/cow/year;
~ 130 Million inseminations per year.
- **The world's breeding sow number over 100 Million:**
use of AI in most breeding centres (95%) at over 4 doses/sow/year;
a minimum of 65 Million inseminations 2x/year.

For **BIASSEX™** to be able to successfully market **S-B DEVICES**


we need a functional AI infrastructure.

c) Road to market

A) Re our bovine **S-B DEVICES** we begin with marketing in WA (1), then Eastern States (2) and to NZ (3).



After 10% penetration of this 6.5 Million market we move to North America (4), Europe (5) and selected OECD associates, like Russia (6a) and China (6b (~95 Million AI/year) then South America's ~30 Million.



B) Re our porcine **S-B DEVICES**: 1. EU (for nearly 30 Million sows; 'no more mutilations' ruling 2018). 2. China's 30 Million; desire for genetic progress. 3. the world's remaining 5 Million 2x yearly sow markets.



C) Re our **S-B DEVICES** for other livestock species: 1. goats



2. buffalos



3. sheep



4. camelids.



6. a) Realistic **S-B DEVICES** profits

(generated out of bovines, porcines and other dairy species)

A) 10% of Australian 🇺🇸 & NZ 🇳🇿 6.5 Million dairy market
= \$2.6 Million YGP.





A 1% penetration of the remaining 128.5 Million dairy market
= \$5.14 Million YGP.

B) A 1% of the potential 65 Mill. 2x annual porcine market
= \$6.5 Million YGP.



C) Adding 0.025% of other milking species = \$5.8 Million YGP.



+




A mere 1% penetration of the above markets
= \$20 Million YGP.

b) The Ask 1

To properly finish our R&D, including an initial trial commercialisation and international patenting of both, the bovine and porcine, **S-B DEVICES**, we are seeking an up-front equity input of **\$500,000 = 3.75 Million shares (15%)**.

Huge potential for growth!



Take a seat on our Board to help us increase the value of your investment or, depart and cash in your temporary loan.

c) The Ask 2

Based upon achievement milestones,
we also need **\$1,500,000 = 6.25 Million shares (25%)**
from 25 Million company shares either as equity or as collateral
(i.e. convertible loan), for a full commercialisation, soon yielding a
YROI of >500%.

For any questions or negotiations, please,
contact:

Josef Pfistershammer

Managing Director/CEO

BIASSEX™ P/L

+61(0)4 2337 7795

josefpf@biassex.com

[**www.biassex.com**](http://www.biassex.com)

Thank you for your attention!